Maze Therapeutics, Inc. Common Stock MAZE Income Statement
| FY'25 | ||
|---|---|---|
| —— | ||
| $108.45M+29.9% | ||
| $34.45M+30.4% | ||
| $142.9M+30.0% | ||
| -$142.9M— | ||
| —— | ||
| —— | ||
| -$131.12M— | ||
| -$3.18-354% | ||
| -$140.5M— | ||
| -$142.9M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Maze Therapeutics, Inc. Common Stock's revenue?
- Maze Therapeutics, Inc. Common Stock (MAZE) generated $187.5M in revenue over the trailing twelve months.
- Is Maze Therapeutics, Inc. Common Stock profitable?
- Maze Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $122.5M over the trailing twelve months, a -65.4% net margin.
- What is Maze Therapeutics, Inc. Common Stock's earnings per share?
- Maze Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.48.
- Where does Maze Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
